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Background: Plasma levels of neutrophil elastase (NE) are elevated in several inflamma-
tory diseases and thus this enzyme might be a critical inflammatory marker. However, the
role of NE in the pathogenesis of pneumonia has not been determined. The association
between the severity of pneumonia and blood levels of inflammatory markers could be
relevant to developing a useful indicator of severity and new therapeutic strategies for
pneumonia.
Methods: We searched for a useful predictive marker and a new therapeutic strategy
against pneumonia, using a prospective, multicenter, population-based investigation.
Several inflammatory markers in the circulation including NE, cytokines, defensins, C-
reactive protein (CRP) and white blood cell (WBC) counts as well as clinical features were
prospectively monitored in 28 adult patients with moderate (n ¼ 11) and severe
pneumonia (n ¼ 17) over a period of 14 days.
Results: The value of plasma NE was the highest at entry and significantly declined 2 days
later. Trends of cytokines, defensins, CRP and WBC counts were similar but blunter.
Microorganisms and the outcome of initial treatment did not significantly affect plasma NE
levels. Baseline values of plasma NE were significantly higher in severe, than in moderate
pneumonia and this difference between the two types of pneumonia persisted longer than
those of any other markers.Elsevier Ltd. All rights reserved.
; ARDS, acute respiratory distress syndrome; NE, neutrophil elastase; IL, interleukin; WBC, white blood
munity acquired pneumonia; HAP, hospital acquired pneumonia; G-CSF, granulocyte colony stimulating
ide-1; HBD-1, 2, human b defensin-1, 2; COPD, chronic obstructive pulmonary disease
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H. Matsuse et al.1522Conclusions: Neutrophil elastase appears to play a critical role in severe pneumonia and
determination of its concentration in blood could be a useful indicator of severity.
Furthermore, clinical trials of anti-NE drugs in patients with severe pneumonia should be
promising.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Pneumonia is a severe, infectious disease of the airways that
is associated with high mortality rates. Severe and pro-
longed pneumonia is resistant to conventional antibiotic
therapy and frequently causes acute lung injury (ALI) or
acute respiratory distress syndrome (ARDS), which require
intensive care including mechanical ventilation. Even when
infection per se has subsided, respiratory failure triggered
by pneumonia can become fatal. Neutrophils frequently
infiltrate the lung tissues or bronchoalveolar lavage (BAL)
fluid of patients with pneumonia.1,2 Neutrophils play a
critical role in protecting the host against microbial
pathogens, but they produce proteolytic enzymes that can
destroy tissue and lead to organ failure. Neutrophils produce
neutrophil elastase (NE) that digests extracellular matrix,
e.g., elastin and collagen. Activated neutrophils invade the
airway during pneumonia, where they produce many
proteolytic enzymes including NE, which cause lung injury
and respiratory failure via pulmonary vascular and alveolar
damage. Proinflammatory cytokines including interleukin
(IL)-6 and IL-8 activate neutrophil functions and might also
be involved in the migration and activation of neutrophils in
pneumonia. Significant increases in NE, IL-6 and IL-8 have
been confirmed at infectious sites of pneumonia,3,4 and IL-8
levels positively correlate with the number of neutrophils or
NE.3 Plasma NE has received focus as a primary inflamma-
tory mediator, since levels are significantly increased in
patients with ARDS, sepsis, post-surgery, trauma and acute
pancreatitis.5–18 However, few studies have measured
plasma NE level in pneumonia,3,19,20 and the time course
of plasma NE in relation to the clinical features of
pneumonia has not been evaluated.
Clarifying the association between the pathogenesis of
pneumonia and inflammatory markers might lead to new
therapeutic strategies for pneumonia and to the identifica-
tion of a predictive marker for its prognosis. Thus, we
measured several proinflammatory markers in the circula-
tion of patients throughout the clinical course of moderate
and severe pneumonia. These included NE, cytokines and
defensins as well as the classical inflammatory markers,
white blood cells (WBC) and C-reactive protein (CRP). We
also compared the clinical features of the patients with the
laboratory findings.Patients and methods
Patients
A prospective, multicenter, population-based investigation
was implemented between July 2003 and March 2004 at 15institutions in Nagasaki, Fukuoka and Saga prefectures in
Japan. Local ethical committees approved the study
protocol and written informed consent was obtained from
all participants. The primary inclusion criterion for the study
was adult patients presenting with pneumonia. Community
acquired pneumonia (CAP) was defined as acute illness that
developed in local residents accompanied by lower respira-
tory tract symptoms or signs including fever, new cough with
or without sputum production, pleuritic chest pain, dyspnea
or altered breath sounds on chest auscultation and a chest
X-ray showing opacity compatible with the presence of
acute pneumonia. Hospital acquired pneumonia (HAP) was
defined as acute pneumonia that developed 48 h or more
after admission to a hospital. Patients with both CAP and
HAP were enrolled in the present study. The secondary
inclusion criterion was moderate or severe pneumonia with
eligibility being determined by the Japanese guidelines for
CAP and HAP21,22 (Table 1). Pneumonia was classified as
being of known etiology using the following criteria: (i)
Mycoplasma pneumoniae, a 4-fold or greater antibody
increase determined by the complement fixation test; (ii)
Chlamydophilia pneumoniae, seropositive IgG and/or IgA
determined using HITAZYME C. pneumoniae (Hitachi Chemical
Co. Ltd., Tokyo, Japan); (iii) Legionella pneumophilia,
isolation of organism from respiratory samples or Legionella
antigen detected in urine; (iv) Streptococcus pneumoniae,
isolation from blood or pleural effusion, or predominant
(X107 CFU/ml) in qualified sputum, or antigen detected in
urine; (v) Haemophilus influenzae, Staphylococcus aureus
and other bacteria, isolation from blood or pleural effusion
or predominant (X107 CFU/ml) in qualified sputum. The
exclusion criteria comprised patients on (i) mechanical
ventilation at entry, (ii) with active pulmonary tuberculosis,
(iii) eosinophilic lung disease or cryptogenic organizing
pneumonia, iv) drug-induced pneumonia, (v) leukemia or
WBC o1000/mm3 or neutrophils o500/mm3, (vi) adminis-
tration of granulocyte-colony stimulating factor (G-CSF) or
anti-cancer drugs within 2 weeks of entry, (vii) liver
dysfunction with X5-fold higher AST or ALT values than
the institutional normal range, (viii) renal dysfunction
indicated by serum creatinine of X3mg/dl before entry,
(ix) systemic steroid therapy within 6 weeks before entry,
(x) pregnancy or nursing children, (xi) participation in
another clinical trial, or (xii) judged inappropriate by the
attending physician.Study design
Blood was collected from eligible patients and chest X-rays
were taken upon entry into the study (day 0) and 1, 2, 3, 7
and 14 days thereafter. These analyses were repeated
when patients were intubated due to respiratory failure.
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Table 1 Severity ratings of pneumonia.
Severity Mild Moderate Severe
Assessment parameters Fulfils at least 5 of the 8
criteria below
Neither mild nor severe Fulfills at least 5 of the 8
criteria below
Extent of infiltration on
chest X-ray
o1/3 area of 1 lung
infiltrated
Neither mild nor severe X2/3 area of 1 lung
infiltrated
Body temperature o37.5 1C Neither mild nor severe X38.6 1C
Pulse rate o100/min Neither mild nor severe X130/min
Respiratory rate o20/min Neither mild nor severe X30/min
Dehydration () () or (+) (+)
White blood cells o10,000/mm3 Neither mild nor severe X20,000/mm3 or o4000/
mm3
C-reactive protein o10mg/dl Neither mild nor severe X20mg/dl
PaO2 470 Torr Neither mild nor severe p60 Torr, SpO2 p90%
Pneumonia was classified as ‘severe’, when patients exhibited cyanosis, impaired consciousness, or shock (systolic pressurep90mmHg
or diastolic pressurep60mmHg), or required a respirator (FiO2435%) to maintain SpO2490%, and oligouria (urine volumeo20ml/h
or o80ml/h) or sepsis, regardless of whether they fulfilled the above criteria.
Plasma neutrophil elastase, inflammatory mediators and clinical features 1523We evaluated plasma levels of NE, IL-6, IL-8, human
neutrophil peptide (hNP)-1, human b-defensin (hBD)-1,
hBD-2, serum CRP as well as peripheral blood count, WBC
fraction, liver and renal functions. Sputum microbiology was
examined at entry before administering antibiotics and if
clinical symptoms or signs worsened despite antibiotic
administration. Vital signs, sputum volume and appearance
were recorded daily during the study, and patients were
asked to record their symptoms including cough, dyspnea
and chest pain on a questionnaire. The following criteria
were scored: cough (0, not present; 1, mild; 2, moderate; 3,
severe) sputum (0, absent; 1,o10ml/day; 2, 11–49ml/day;
3, 50–99ml/day; 4, 4100ml/day) sputum appearance(M,
mucous; MP, mucopurulent; P, purulent) Fletcher–Hugh–
Jones (FHJ) grades of dyspnea (0, grade I; 1, grade II; 2,
grade III and above) chest pain (0, absent; 1, present) rale
(0, absent; 1, mild; 2, moderate to severe) and dehydration
(0, absent; 1, present) cyanosis (0, absent; 1, present).
Intervention and outcome measures
Attending physicians were permitted to administer conven-
tional medication to treat pneumonia and its complications
including antibiotics and glucocorticoids with the exceptions
of new drugs under clinical investigation, sivelestat,
ulinastatin, G-CSF and anti-cancer drugs. Full supportive
care such as oxygen was provided as required. The outcome
of the patients was followed up for at least 27 days after
entry.
Measurement of plasma NE, defensins and cytokines
(IL-6 and IL-8)
Blood samples collected into EDTA2Na for NE, IL-6, IL-8,
hNP-1, hBD-1 and hBD-2 assays were stored frozen. All
assays except for hNP-1, hBD-1 and hBD-2 were performed
at the central laboratory (Mitsubishi Chemical Co. Ltd.,
Tokyo, Japan). Levels of hNP-1, hBD-1 and hBD-2 were
determined by RIA at the laboratory of Miyazaki UniversitySchool of Medicine (Miyazaki, Japan) as described.23–25
Plasma NE levels were determined by latex coagulation
using Ecoline PMN elastase (Diagnostica Merck, Germany).
Plasma IL-6 and IL-8 concentrations were determined using a
Human IL-6 Chemiluminescent Immunoassay (R&D Systems,
USA) and an IL-8 ELISA (BIOSOURCE, Belgium), respectively.
Statistical analysis
Results are expressed as means7standard deviation (SD)
unless otherwise noted. Paired and unpaired data were
analyzed using Wilcoxon’s rank sum test and the Mann–
Whitney U-test, respectively. Ratios were evaluated using
Fisher’s exact probability test and correlations were
examined using Spearman’s correlation index. A two-tailed
p-value of 0.05 was considered significant.
Results
Demographic data from all enrolled patients
We enrolled 29 patients from 15 institutions during the study
period (1 patient each from 7 institutions, 2 patients each
from 5 institutions, 3 patients from 1 institution and 4
patients each from 2 institutions. Among 29 patients, one
was excluded because he was treated with oral steroids for
interstitial pneumonia before entry. Thus data were
obtained from the remaining 28 patients. Tables 2 and 3
show the characteristics of the patients and the micro-
biological results, respectively. Elderly males predominated
and 92.9% of the patients (26/28) were older than 65 yr.
Analysis of the nature of the pneumonia revealed that the
ratios of CAP and classical bacterial pneumonia were higher
than those of HAP and atypical pneumonia. Approximately
half of the patients (46.4%) also had other concurrent
chronic respiratory diseases. The causative microorganisms
were identified in 64.3% (18/28) of the patients. The most
frequently isolated pathogen was S. pneumoniae followed
by H. influenzae and other Streptococcus species (Table 3).
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Table 2 Patients’ characteristics.
Total Moderate Severe
Number of patients 28 11 17
Male 17 (60.7) 8 (72.7) 9 (52.9)
Age 77.179.9 77.577.2 76.9711.6
Community
acquired
26 (92.9) 10 (90.9) 16 (94.1)
Respiratory
complications
13 (46.4) 4 (36.4) 9 (52.9)
Smoking history 10 (38.5) 4 (44.4) 6 (35.3)
Classic bacterial
pathogens
25 (89.3) 11 (100) 14 (82.4)
Causative pathogens
identified
18 (64.3) 7 (63.6) 11 (64.7)
Parentheses show percentages.
Table 3 Distribution of causative microorganisms.
Total Moderate Severe
Number of
patients
28 11 17
S. pneumoniae 7 (20.5) 2 (18.2) 5(29.4)
H. influenzae 4 (14.3) 3 (27.2) 1 (5.9)
Streptococcus
spp.
2 (7.1) 0 (0.0) 2 (11.8)
Chlamydophilia 2 (7.1) 0 (0.0) 2 (11.8)
S. agalactiae 1 (3.6) 1 (9.1) 0 (0.0)
S. aureus 1 (3.6) 0 (0.0) 1 (5.9)
P. aeruginosa 1 (3.6) 0 (0.0) 1 (5.9)
K. pneumoniae 1 (3.6) 0 (0.0) 1 (5.9)
K. oxytoca 1 (3.6) 0 (0.0) 1 (5.9)
Neisseria spp. 1 (3.6) 1 (9.1) 0 (0.0)
E. coli 1 (3.6) 0 (0.0) 1 (5.9)
Unknown 10 (35.7) 4 (36.4) 6 (35.3)
Parentheses show percentages.
H. Matsuse et al.1524Clinical symptoms and blood inflammatory markers
Dehydration and cyanosis disappeared at 7 days after entry,
whereas other symptoms continuously declined, but per-
sisted even after 7–14 days after entry. Fig. 1 shows changes
in blood levels of inflammatory markers. The values of
plasma NE were the highest at entry and significantly
declined 2 days thereafter. The trends in IL-6, IL-8, hNP-1
and WBC were similar to those of plasma NE, but the
changes were modest. In contrast, serum CRP peaked at 1
day after entry and significantly declined 3 days thereafter.
We did not identify any distinct changes in blood levels of
defensins. At entry, plasma NE levels were significantly
correlated with serum CRP levels (R2 ¼ 0.458, po0.05). We
did not find a significant correlation at entry between
plasma NE level and any other clinical parameters in any of
the patients (data not shown).Subgroup analysis based on severity of pneumonia
Subgroup analysis based on pneumonia severity showed that
the characteristics of patients were essentially identical
regardless of whether the pneumonia was moderate or
severe (Table 2). In comparison with moderate pneumonia,
baseline values of NE, IL-8, hBD-1 and CRP were significantly
higher in severe pneumonia (Table 4). The distribution of the
causative pathogens was essentially identical between the
two types of pneumonia (Table 3). The duration of
significant differences between moderate and severe
pneumonia was longer in plasma NE (4 days) than in serum
CRP (2 days) after entry (Fig. 2). No other parameters
significantly differed throughout the clinical course except
for hNP-1 and hBD-1 and the clinical features of moderate
and severe pneumonia were almost identical (data not
shown).
Outcome
The microorganisms and outcome of initial treatment did
not significantly affect plasma NE levels (data not shown).
Of the 28 patients, 4 (14.3%) required mechanical ventila-
tion. All of these had underlying chronic obstructive
pulmonary disease (COPD) and survived on mechanical
ventilation. Plasma NE levels on the day of intubation in 2
of these 4 patients increased compared with those 1 day
before intubation. During the study period, 1 patient with
CAP died on day 8 and the other patient with HAP died 27
days after the initiation of antimicrobial medication. Plasma
NE levels in these patients did not obviously differ from
those in surviving patients. The average hospitalization
period for all patients was 47.2767.2 days and only those
with CAP were hospitalized for 35.8726.8 days.
Discussion
Pneumonia is one of the most frequent causes of mortality in
Japan along with neoplasms, cardiac and cerebrovascular
diseases. Pneumonia develops at all ages, but especially in
the elderly, and mortality increases with age.26 The
morbidity and mortality rates of pneumonia will almost
certainly increase as society ages. According to the current
international guidelines for the treatment of pneumonia,
severity represents a determinant for the decision of initial
therapy. Thus to develop a simple and non-invasive marker
predicting the severity of pneumonia will be useful for
clinicians. The results of the present study indicated that
plasma NE levels could be a good systemic marker for the
severity of both CAP and HAP. However, we could not
establish a significant association among plasma NE,
causative organisms and outcome of initial treatment,
probably due to the small study cohort. Current recom-
mended therapies for pneumonia include antibiotics and
supportive care such as oxygen. However, because causative
microorganisms can be identified during the early phase in
only 40–60% of patients with pneumonia,27,28 antibiotic
therapy is often initiated empirically to treat pneumonia
based on symptoms, signs and chest radiography, but this
strategy carries the risk of increasing the incidence of
antibiotic-resistant bacteria, which then leads to severe
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Figure 1 Time course of blood inflammatory markers in all patients. Symbols represent means (n ¼ 28)7SD.**po0.01 vs. day 0.
Plasma neutrophil elastase, inflammatory mediators and clinical features 1525pneumonia and death. Antibiotic therapy thus has a critical
limitation and a new therapeutic strategy is required that
could support the efficacy of antibiotics by acting on the
pathogenesis of pneumonia irrespective of causative patho-
gens. In fact, therapies with immunoglobulin, G-CSF and
corticosteroids are under investigation, but their effective-
ness in treating pneumonia remain controversial.29–32 The
present study evaluated several blood inflammatory markers
and clinical features of moderate and severe pneumonia and
found that plasma NE levels seem to represent a sensitive
marker and potential therapeutic target for severe
pneumonia.
Activated neutrophils rapidly release the neutral serine-
protease NE from cytoplasmic granules into the extracel-
lular space with some NE remaining bound to the neutrophil
plasma membrane.33 The enzyme has a wide range of anti-
microorganism activity34 and reduces the immunity of mice
that are genetically deficient in NE against Gram-negative
bacteria,35 suggesting that NE plays a critical role in host
defense. Antiproteases such as a1 antitrypsin, inhibit
proteases including NE by interacting with their catalytic
sites, thereby preventing them from damaging normal
structures. In the normal lung, antiproteases prevent the
deleterious effects of proteases, because they are present
at higher concentrations than proteases, providing an
‘‘antiprotease screen.’’ However, antiproteases are de-graded by oxidants such as O2
, H2O2, OH and OCl
 that
are generated during infective lung disease. Therefore, the
protease concentration in the local milieu of infective lung
disease overwhelms the local antiprotease protective
screen, which results in excessive extracellular protease
activity, leading to the degradation of lung tissue.36 In the
pathogenesis of ALI, NE plays an important role in lung
inflammatory responses.35 Additionally, an NE inhibitor is
useful in animal models of pneumonia.37–40 Among the
inflammatory markers in the circulation examined in the
present study, plasma NE levels were the most significantly
different between moderate and severe pneumonia.
Although others have reported that proinflammatory cyto-
kine and defensin levels increase in pneumonia,23,25,41
changes in these agents were not as evident as those in
the NE levels in the present study. Additionally, we found
that plasma levels of proinflammatory cytokines and
defensins did not significantly correlate with NE. The
relatively small patient cohort in the present study might
explain this discrepancy. One report indicates that NE
concentrations in BAL fluids significantly correlate with
IL-8 levels.3 Since we determined NE and cytokines in
plasma, and not in BAL, we might have missed a significant
correlation between these markers. Levels of CRP, an acute
phase inflammatory marker, peaked at day 1 and decreased
more slowly than those of NE, which is stored and then
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Figure 2 Time course of blood inflammatory markers in moderate
(closed diamonds) (n ¼ 11) and severe (open squares) pneumonia (
Table 4 Baseline data.
Total Moderate Severe
Number of
patients
28 11 17
BT (1C) 38.270.9 38.471.0 38.070.9
(36.4–40.5) (36.6–40.5) (36.4–39.1)
RR (/min) 27.776.8 25.675.2 29.077.5
(18–42) (18–32) (18–42)
HR (/min) 106.0717.5 101.7719.5 108.9716.1
(75–142) (75–142) (80–131)
PaO2 (Torr) 63.0728.3 73.7740.8 55.179.0
(41.0–194.1) (48.0–194.1) (41.0-73.0)
Elastase (ng/ml) 204.87159.3 119.9764.3 259.87179.1**
(47.0–717.0) (47.0–240.0) (84.0–717.0)
IL-6 (pg/ml) 1905.173799.6 403.87465.9 2876.574655.6
(27.0–12600.0) (47.7–1570.0) (27.0–12600.0)
IL-8 (pg/ml) 29.7738.9 20.0730.5 36.0743.2*
(8.0–154.0) (8.0–110.0) (8.0–154.0)
hNP-1(ng/ml) 2108.372003.8 1266.97742.8 2652.772372.6
(226.0–8715.0) (226.0–2231.0) (676.0–8715.0)
hBD-1(ng/ml) 8.974.2 6.972.1 10.274.7*
(4.0–21.7) (4.0–0.6) (4.8–21.7)
hBD-2(pg/ml) 435.17344.1 297.87200.1 523.97391.8
(21.2–1420.3) (41.6–659.9) (21.2-1420.3)
WBC (/mm3) 12614.375360.9 12300.974096.8 12817.176156.0
(6130–31400) (6460–18600) (6130–31400)
CRP (mg/dl) 18.5710.0 14.379.4 21.379.7*
(0.2–34.8) (0.4–26.0) (0.2–34.8)
Parentheses show ranges. *po0.05 and **po0.01 vs. moder-
ate pneumonia.
H. Matsuse et al.1526released following neutrophil activation, whereas CRP is
produced in the liver by inflammatory cytokines including
IL-6.42 These differences might become more apparent
when these mediators appear. Since the clinical features
neither significantly correlated with blood inflammatory
markers nor significantly differed between moderate and
severe pneumonia, clinical features alone are not sufficient
prognostic markers for pneumonia.
Despite the small patient cohort, plasma levels of NE
immediately increased before intubation for respiratory
failure, confirming NE as having prognostic value in
severe pneumonia. Future studies of more patients are
required to confirm the association between mortality and
plasma NE levels. Besides NE, other investigations of blood
inflammatory markers in pneumonia have revealed that
procalcitonin is a useful marker of the prognosis of severe
pneumonia, and can predict the microbial etiology in
milder forms.43 The association between plasma NE levels
and these novel inflammatory markers should also be
evaluated.
In conclusion, the present study suggests that NE plays a
critical role in the pathogenesis of pneumonia. In addition,
plasma NE concentrations are apparently useful indicators
of severity and their determination facilitates the selection
of appropriate treatment in the early stages of disease,
which will prevent aggressive progression to ARDS. Further-
more, clinical trials of anti-NE drugs in patients with severe
pneumonia should be promising.pg/ml)
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